Karacaoglan, V. Et Al. 2017. Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients. TURKISH JOURNAL OF MEDICAL SCIENCES , vol.47, no.2 , 554-562.

Karacaoglan, V., ADA, A. O., Bilgen, S., Cetinkaya, G. T., Soydas, E., Kunak, C. S., ... Alpar, S. M.(2017). Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients. TURKISH JOURNAL OF MEDICAL SCIENCES , vol.47, no.2, 554-562.

Karacaoglan, Volkan Et Al. "Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients," TURKISH JOURNAL OF MEDICAL SCIENCES , vol.47, no.2, 554-562, 2017

Karacaoglan, Volkan Et Al. "Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients." TURKISH JOURNAL OF MEDICAL SCIENCES , vol.47, no.2, pp.554-562, 2017

Karacaoglan, V. Et Al. (2017) . "Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients." TURKISH JOURNAL OF MEDICAL SCIENCES , vol.47, no.2, pp.554-562.

@article{article, author={Volkan Karacaoglan Et Al. }, title={Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients}, journal={TURKISH JOURNAL OF MEDICAL SCIENCES}, year=2017, pages={554-562} }